Bispecifics Network Aims to Help Practices Implement New Cancer Treatments

The year-long series will focus on operationalizing bispecific antibodies in oncology practice.

Apr. 14, 2026 at 2:14am

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph showing the ghostly, glowing molecular structure of bispecific antibodies, conceptually illustrating the complex inner workings of this innovative cancer treatment technology.A translucent X-ray image reveals the intricate molecular structure of bispecific antibodies, a new class of cancer treatments that oncology practices are working to implement.Today in Nashville

The Bispecifics Network, a new initiative, will host a series of discussions to help practices and health systems implement bispecific antibodies, a new class of cancer treatments. The goal is to address topics like practice readiness and care delivery models as these agents move into earlier lines of therapy.

Why it matters

Bispecific antibodies are a rapidly evolving area of cancer treatment, but their implementation in real-world oncology practices can be complex. The Bispecifics Network aims to provide guidance and share best practices to ensure these innovative therapies can be effectively utilized to benefit patients.

The details

The Bispecifics Network will kick off its year-long series at the upcoming Academy of Managed Care Pharmacy (AMCP) 2026 meeting in Nashville, Tennessee, from April 13-16. The discussions will focus on helping practices and health systems navigate the operational challenges of incorporating bispecific antibodies into their cancer care delivery.

  • The Bispecifics Network series will launch at the AMCP 2026 meeting from April 13-16, 2026.
  • The year-long series will continue after the initial kickoff at AMCP 2026.

The players

Bispecifics Network

A new initiative aimed at helping oncology practices and health systems implement bispecific antibodies, a novel class of cancer treatments.

Susan Cantrell

CEO of the Academy of Managed Care Pharmacy (AMCP), the organization hosting the 2026 meeting where the Bispecifics Network will launch its series.

The American Journal of Managed Care® (AJMC®)

A publication that will be covering the AMCP 2026 meeting and the Bispecifics Network's activities.

Got photos? Submit your photos here. ›

What they’re saying

“The goal is to discuss ways to help practices and health systems implement bispecific antibodies and touch on topics such as practice readiness and care delivery models as these agents move into earlier lines of therapy.”

— Susan Cantrell, CEO, Academy of Managed Care Pharmacy (AMCP)

What’s next

The Bispecifics Network will host a series of discussions throughout the year following the initial launch at the AMCP 2026 meeting, with the goal of providing practical guidance to oncology practices on implementing this new class of cancer treatments.

The takeaway

As bispecific antibodies become more prevalent in cancer care, the Bispecifics Network aims to play a crucial role in helping oncology practices and health systems navigate the operational complexities of adopting these innovative therapies to ensure patients can access and benefit from these advancements.